This stock started to move last Wednesday.The Geron news may have accelerated the move but it started 2 days earlier. Those who have followed this stock for any time know that news is expected any time about three big indications.
The Phase IIb stroke study has been halted because of unrelated news from europe about problems with EPO given in larger doses ,days earlier than in the SSS protocol. The SSS study has passed all safety tests. This indication alone would have a $10 Billion potential market. There is at present very litlle that can be done to repair the brain damage caused by a stroke.
The Phase IIa Traumatic Brain Injury study was also halted. This is a potential $12 Billion indication. Military ,sports and traffic accident TBI injury patients have very little to help them recover.
There could be a Phase II MS study start up any time as there are preclinical studies which show a combination of drugs which result in the re-mylination of nerve lining damaged by MS. This is possibly the largest indication..over $12 Billion ....as it would revolutionize the treatment of MS.
Add to this the fact that the stimulation of the patients own stem cells overcomes the rejection problems associated with using someone elses(embryonic) stem cells...puts this company far ahead of the competition. It is little known because it is Canadian and not on a U.S. exchange.